August 2, 2020

We are happy to announce that Kebotix has joined C2I Accelerator. Kebotix fits the mold of our most successful tenants. They bring a highly experienced, integrated team to C2I which makes them ripe for taking advantage of our unique offerings that no other accelerators in the Boston area provide....

July 24, 2020

Congratulations to our alumna, RootPath, on raising $11 Million Series A funding to accelerate clinical translation of their personalized, highly-potent T cell therapy powered by their proprietary Synthetic Immunology Platform™!

Rootpath will use the Series A funding to validate their tumor-reactive T ce...